Adalimumab BS Daiichi Sankyo
Adalimumab biosimilar developed by Daiichi Sankyo. Reference product Humira.
About Adalimumab BS Daiichi Sankyo
Adalimumab BS Daiichi Sankyo was the second adalimumab biosimilar approved in Japan, in January 2021. Daiichi Sankyo is one of Japan's largest pharmaceutical companies and markets a small biosimilar portfolio alongside its own medicines. The product covers the main rheumatology, dermatology and gastroenterology uses of the reference product in Japan.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Adalimumab BS Daiichi Sankyo
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Adalimumab BS Daiichi Sankyo holds an approval, these are the other adalimumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| PMDA | 3 | Celltrion (Yuflyma), Fujifilm Kyowa Kirin Biologics (Hulio), Mochida Pharmaceutical (Adalimumab BS MA) |
Chronology
- PMDAJan 2021Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning adalimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant